New Zealand’s government recently committed an extra $604 million to Pharmac, the country’s medicines funding agency, specifically to expand access to cancer treatments. That injection is expected to cover around 26 new cancer medicines, including immunotherapies that work by helping the body’s own immune system attack tumours. For anyone facing a cancer diagnosis or supporting someone who is, the question isn’t just what’s funded — it’s when, for whom, and how the process actually works. Here’s what you actually need to know.
Disclosure: Some links on this page are affiliate links. If you make a purchase through them, Britwealth may earn a commission at no extra cost to you. We only include products and services that are relevant to the topic.
This article is general information only and does not constitute professional advice. For your specific situation, consult a qualified professional.
These aren’t small changes. The first two drugs — pembrolizumab (Keytruda) and nivolumab (Opdivo) — are checkpoint inhibitors, a type of immunotherapy that blocks proteins cancer cells use to hide from the immune system. They’ve been available privately in New Zealand for years, but at significant cost. Now, from October and November respectively, eligible patients can access them through the public system. That shift alone changes the landscape for several cancers, including advanced triple-negative breast cancer, head and neck cancer, colorectal cancer, bladder cancer, Hodgkin lymphoma, and kidney cancer.
But the full list of 26 medicines hasn’t been announced yet. Pharmac can’t name them until its internal procurement process is complete. That means there’s a gap between the funding promise and the practical reality of what’s available. If you’re trying to plan treatment or understand your options, that gap matters. For a deeper look at how New Zealand’s health funding system works alongside personal financial planning, you might find understanding the waiting period for personal insurance in New Zealand useful context.
Immunotherapy works differently from chemotherapy. Instead of killing cancer cells directly, it essentially takes the brakes off your immune system so it can recognise and attack tumours. That’s why it’s sometimes called a checkpoint inhibitor.
What I tend to notice is that people assume immunotherapy is a single treatment. It’s not. Different drugs target different checkpoints, and they work better for some cancers than others. The two now being funded are both PD-1 inhibitors, which means they block the PD-1 protein on immune cells. That’s a well-studied pathway, but it’s not the only one. Future funded medicines may target different mechanisms entirely.
What changes when immunotherapy funding is delayed or unclear
The gap between a funding announcement and actual availability creates real consequences. Pharmac estimates the $604 million will cover 26 cancer medicines, but the first two won’t be accessible until October and November. For someone diagnosed today with advanced triple-negative breast cancer, that’s a waiting period measured in months, not weeks. During that time, the standard treatment pathway — chemotherapy, surgery, radiation — continues. But if immunotherapy could improve outcomes, the delay matters.
There’s also the question of eligibility. Even after a drug is funded, not every patient qualifies. Pharmac sets specific criteria: cancer type, stage, previous treatments tried, and sometimes biomarker status (like PD-L1 expression levels). If you don’t meet those criteria, the drug isn’t available to you through the public system, even though it’s technically funded. That’s a nuance that often gets lost in the headlines.
Another layer is the non-cancer medicines also included in the funding. Pharmac says the $604 million will also cover 28 other medicines for conditions like infections, respiratory issues, osteoporosis, and mental health. That’s important because it means the cancer funding isn’t isolated — it’s part of a broader medicines budget that has to balance competing priorities. If you’re wondering how this fits into your broader financial planning, especially around health insurance or savings for treatment, investing for your kids’ future might offer a different angle on long-term health cost planning.
Where people get caught out by immunotherapy funding
Assuming funding means immediate access
The most common misunderstanding is that once Pharmac announces funding, the drug is available the next day. In reality, there’s a procurement process that includes negotiating with the supplier, setting eligibility criteria, and public consultation. Pembrolizumab was announced with a 1 October start date — that’s a lead time of several months. For nivolumab, it’s 1 November. During that window, patients may need to pay privately or wait.
Not checking eligibility criteria before planning treatment
Even after a drug is funded, it’s only for specific patient groups. For example, pembrolizumab is funded for advanced triple-negative breast cancer, head and neck cancer, colorectal cancer, bladder cancer, and Hodgkin lymphoma — but not for all stages or subtypes of those cancers. If your cancer doesn’t match the exact criteria, you won’t get it through the public system. That’s why it’s worth reviewing the criteria on Pharmac’s website or discussing with your oncologist before assuming you qualify.
Overlooking the public consultation window
Pharmac consults publicly before finalising funding proposals. That’s your chance — or your clinician’s — to submit feedback on proposed criteria. Many people don’t realise this step exists, so they miss the opportunity to influence what’s covered. The consultation period is typically open for a few weeks, and submissions can come from individuals, patient groups, or health professionals. If you’re affected by a future funding decision, watching Pharmac’s webpage for consultation notices is worth doing.
Confusing immunotherapy with other cancer treatments
Immunotherapy isn’t chemotherapy, and it isn’t targeted therapy either. It has different side effects — often immune-related inflammation in organs like the lungs, liver, or skin — and different response patterns. Some patients respond dramatically, others not at all. The funding criteria reflect that uncertainty, which is why biomarkers like PD-L1 expression are sometimes required. Assuming immunotherapy is a universal upgrade over chemo can lead to unrealistic expectations.
For anyone navigating these decisions, having access to clear legal or financial guidance can help. A service like JustAnswer Finance connects you with professionals who can explain how health funding interacts with insurance, income protection, or treatment costs.
How to navigate immunotherapy funding in New Zealand right now
Check the current funded list and start dates
As of now, pembrolizumab (Keytruda) is funded from 1 October for eligible patients with advanced triple-negative breast cancer, head and neck cancer, colorectal cancer, bladder cancer, and Hodgkin lymphoma. Nivolumab (Opdivo) follows on 1 November for eligible kidney cancer patients. These are the only two immunotherapy drugs with confirmed funding dates from the $604 million boost. For any other cancer type, the standard publicly funded treatments still apply — and you’ll need to wait for Pharmac’s next announcements.
Understand the eligibility criteria before you need them
Pharmac publishes the specific criteria for each funded medicine on its website. These typically include cancer type, stage, prior treatments, and sometimes biomarker results. For pembrolizumab, for example, you’ll need to have a confirmed diagnosis of one of the listed cancers at an advanced stage, and your oncologist will need to submit an application. It’s not automatic — your specialist has to apply through the standard Pharmac access process. Knowing the criteria in advance means you can discuss with your doctor whether you’re likely to qualify, and if not, what alternatives exist.
Watch for public consultation opportunities
Before Pharmac finalises funding for any new medicine, it opens a public consultation. This is where patients, clinicians, and the public can comment on the proposed criteria. If you or someone you know could benefit from a future immunotherapy drug, monitoring Pharmac’s consultation page and submitting feedback can influence the final criteria. It’s a straightforward process — usually an online form with a few questions — and it’s one of the few ways individuals can directly shape what’s covered.
Plan for the gap between announcement and availability
If a drug is announced but not yet funded, you have options. Some patients choose to pay privately for treatment during the gap, though costs can be significant — pembrolizumab infusions can run into tens of thousands of dollars per year. Others discuss clinical trial options with their oncologist, or adjust their treatment timeline to align with the funding start date. Having a conversation with your specialist about what’s realistic for your specific situation is the most practical step.
For those dealing with the legal or contractual side of treatment — like insurance claims, employment issues during treatment, or understanding your rights — JustAnswer Business Law can connect you with a lawyer who understands New Zealand’s health and employment regulations.
Frequently asked questions about cancer immunotherapy coverage in New Zealand
Will immunotherapy be funded for all cancers eventually? ▾
Can I get pembrolizumab privately before October? ▾
What if my cancer isn’t on the funded list? ▾
How do I know if I’m eligible for funded immunotherapy? ▾
Does private health insurance cover immunotherapy in New Zealand? ▾
What’s the difference between pembrolizumab and nivolumab? ▾
The next phase of cancer treatment funding in New Zealand
The $604 million boost is the largest single increase to Pharmac’s cancer medicines budget in recent memory, but it’s not a one-time fix. Pharmac will continue to assess new medicines as evidence emerges, and the public consultation process means patients have a real — if limited — say in what gets funded next. The two immunotherapies rolling out this year are likely just the beginning, but the pace depends on negotiations, supplier agreements, and budget priorities. For anyone affected by cancer right now, the practical takeaway is simple: know the criteria, watch for consultations, and talk to your specialist about timing.
Remember: this article is general information only. For advice on your specific situation, speak to a qualified professional.
If this was useful, you might also want to read Supercharge KiwiSaver returns in 2025.
Sources and Further Reading
Understanding personal insurance options for accident coverage in NZ — Explains how accident insurance interacts with public health funding, useful context for treatment planning.
Te Aho o Te Kahu – Cancer Control Agency (2024). Understanding Cancer Immunotherapy Coverage In New Zealand. 🔗
Pharmac (2024). First cancer medicine decision following Pharmac funding boost. 🔗
Pharmac (2024). Pharmaceutical Budget Advisory Committee updates. 🔗
